Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 18/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 18/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307301 | 0.89 | PIK3CA (0.65) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2437357 | 0.81 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL390033 | 0.81 | PIK3CD (0.77) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2466623 | 0.80 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2463758 | 0.80 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5251923 | 0.80 | PIK3CA (0.41) | PIK3CDPIK3CAPIK3CG | |
| SCHEMBL4555688 | 0.80 | PIK3CA (0.41) | PIK3CDPIK3CAPIK3CG | |
| SCHEMBL1859684 | 0.79 | PIK3CA (0.75) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3608706 | 0.79 | PIK3CD (0.77) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2465953 | 0.79 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365810-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |